Table 1. Clinical features of patients... | American Society of Hematology

Table 1.

Clinical features of patients at diagnosis, as assessed by WB

	No.	%
Total	94	100
Mean age, y (range)	56 (34-77)	NA
Female	38	40.4
Mean BM PCs, % (range)	47 (5-99)	NA
M component
IgG	53	56.4
IgA	22	23.4
Light chain	17	18.1
Nonsecretory	2	2.1
K	60	65.2
Mean Hb level, g/dL (range)	11 (5.6-16)	NA
Bone lytic lesions
0	26	27.6
1 or more	68	72.3
Salmon and Durie stage
I	4	4.2
II	27	28.7
III	63	67.0
Mean creatinine level, mg/dL (range)	2 (0.4-8.4)	NA
Del13q^*	18	50.0
Mean 2-microglobulin level, g/L (range)†	5 (1.1-22.8)	NA
First-line treatment
Conventional	28	29.8
Thalidomide plus conventional	4	4.2
Autologous or allogeneic SCT	62	66.0

	No.	%
Total	94	100
Mean age, y (range)	56 (34-77)	NA
Female	38	40.4
Mean BM PCs, % (range)	47 (5-99)	NA
M component
IgG	53	56.4
IgA	22	23.4
Light chain	17	18.1
Nonsecretory	2	2.1
K	60	65.2
Mean Hb level, g/dL (range)	11 (5.6-16)	NA
Bone lytic lesions
0	26	27.6
1 or more	68	72.3
Salmon and Durie stage
I	4	4.2
II	27	28.7
III	63	67.0
Mean creatinine level, mg/dL (range)	2 (0.4-8.4)	NA
Del13q^*	18	50.0
Mean 2-microglobulin level, g/L (range)†	5 (1.1-22.8)	NA
First-line treatment
Conventional	28	29.8
Thalidomide plus conventional	4	4.2
Autologous or allogeneic SCT	62	66.0

WB indicates Western blotting; NA, not applicable; BM, bone marrow; PCs, plasma cells; Hb, hemoglobin; SCT, stem cell transplantation.

Assessed by fluorescence in situ hybridization, available in 36 patients.

β₂-microglobulin available in 77 patients.